annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
1043858606 | rs6265 | rs6265 | BDNF | CC | 3 | Efficacy | antidepressants;citalopram;paroxetine | Depressive Disorder | Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine but less likely to respond to citalopram or antidepressants as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a pa... | https://www.pharmgkb.org/clinicalAnnotation/1043858606 |
1043858606 | rs6265 | rs6265 | BDNF | CT | 3 | Efficacy | antidepressants;citalopram;paroxetine | Depressive Disorder | Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine or antidepressants as compared to patients with the CC or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants. | https://www.pharmgkb.org/clinicalAnnotation/1043858606 |
1043858606 | rs6265 | rs6265 | BDNF | TT | 3 | Efficacy | antidepressants;citalopram;paroxetine | Depressive Disorder | Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine or antidepressants but more likely to respond to citalopram as compared to patients with the CC or CT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a pa... | https://www.pharmgkb.org/clinicalAnnotation/1043858606 |
1043858615 | rs5443 | rs5443 | GNB3 | CC | 4 | Efficacy | antidepressants | Major Depressive Disorder | Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.pharmgkb.org/clinicalAnnotation/1043858615 |
1043858615 | rs5443 | rs5443 | GNB3 | CT | 4 | Efficacy | antidepressants | Major Depressive Disorder | Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. | https://www.pharmgkb.org/clinicalAnnotation/1043858615 |
1043858615 | rs5443 | rs5443 | GNB3 | TT | 4 | Efficacy | antidepressants | Major Depressive Disorder | Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant trea... | https://www.pharmgkb.org/clinicalAnnotation/1043858615 |
1043858632 | rs1800532 | rs1800532 | TPH1 | GG | 4 | Efficacy | antidepressants;citalopram;escitalopram;fluoxetine;paroxetine | Major Depressive Disorder | Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to citalopram treatment as compared to patients with the GT or TT genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinic... | https://www.pharmgkb.org/clinicalAnnotation/1043858632 |
1043858632 | rs1800532 | rs1800532 | TPH1 | GT | 4 | Efficacy | antidepressants;citalopram;escitalopram;fluoxetine;paroxetine | Major Depressive Disorder | Patients with the GT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical fac... | https://www.pharmgkb.org/clinicalAnnotation/1043858632 |
1043858632 | rs1800532 | rs1800532 | TPH1 | TT | 4 | Efficacy | antidepressants;citalopram;escitalopram;fluoxetine;paroxetine | Major Depressive Disorder | Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical fac... | https://www.pharmgkb.org/clinicalAnnotation/1043858632 |
1043858637 | rs7572857 | rs7572857 | CEP68 | AA | 3 | Toxicity | aspirin | Asthma | Patients with the AA genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858637 |
1043858637 | rs7572857 | rs7572857 | CEP68 | AG | 3 | Toxicity | aspirin | Asthma | Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858637 |
1043858637 | rs7572857 | rs7572857 | CEP68 | GG | 3 | Toxicity | aspirin | Asthma | Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858637 |
1043858642 | rs7179742 | rs7179742 | FSIP1 | AA | 3 | Toxicity | aspirin | Asthma | Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858642 |
1043858642 | rs7179742 | rs7179742 | FSIP1 | AG | 3 | Toxicity | aspirin | Asthma | Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858642 |
1043858642 | rs7179742 | rs7179742 | FSIP1 | GG | 3 | Toxicity | aspirin | Asthma | Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858642 |
1043858651 | rs3856806 | rs3856806 | PPARG | CC | 3 | Toxicity | aspirin | Asthma | Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity. | https://www.pharmgkb.org/clinicalAnnotation/1043858651 |
1043858651 | rs3856806 | rs3856806 | PPARG | CT | 3 | Toxicity | aspirin | Asthma | Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity. | https://www.pharmgkb.org/clinicalAnnotation/1043858651 |
1043858651 | rs3856806 | rs3856806 | PPARG | TT | 3 | Toxicity | aspirin | Asthma | Patients with the TT genotype and asthma may have an increased risk for aspirin hypersensitivity as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity. | https://www.pharmgkb.org/clinicalAnnotation/1043858651 |
1043858656 | rs2243250 | rs2243250 | IL4 | CC | 3 | Toxicity | aspirin | Asthma | Patients with the CC genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858656 |
1043858656 | rs2243250 | rs2243250 | IL4 | CT | 3 | Toxicity | aspirin | Asthma | Patients with the CT genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858656 |
1043858656 | rs2243250 | rs2243250 | IL4 | TT | 3 | Toxicity | aspirin | Asthma | Patients with the TT genotype and asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858656 |
1043858661 | rs2228079 | rs2228079 | ADORA1 | GG | 3 | Toxicity | aspirin | Asthma | Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858661 |
1043858661 | rs2228079 | rs2228079 | ADORA1 | GT | 3 | Toxicity | aspirin | Asthma | Patients with the GT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858661 |
1043858661 | rs2228079 | rs2228079 | ADORA1 | TT | 3 | Toxicity | aspirin | Asthma | Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858661 |
1043858666 | rs16851030 | rs16851030 | ADORA1 | CC | 3 | Toxicity | aspirin | Asthma | Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858666 |
1043858666 | rs16851030 | rs16851030 | ADORA1 | CT | 3 | Toxicity | aspirin | Asthma | Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858666 |
1043858666 | rs16851030 | rs16851030 | ADORA1 | TT | 3 | Toxicity | aspirin | Asthma | Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858666 |
1043858675 | rs1613662 | rs1613662 | GP6 | AA | 3 | Efficacy | aspirin | Coronary Artery Disease | Patients with the AA genotype were not studied but patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858675 |
1043858675 | rs1613662 | rs1613662 | GP6 | AG | 3 | Efficacy | aspirin | Coronary Artery Disease | Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858675 |
1043858675 | rs1613662 | rs1613662 | GP6 | GG | 3 | Efficacy | aspirin | Coronary Artery Disease | Patients with the GG genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858675 |
1043858680 | rs11587213 | rs11587213 | FCER1G | AA | 3 | Toxicity | aspirin | Asthma | Patients with the AA genotype and asthma may have an increased risk for aspirin sensitivity but patients with chronic urticaria may have a decreased risk for aspirin sensitivity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensiti... | https://www.pharmgkb.org/clinicalAnnotation/1043858680 |
1043858680 | rs11587213 | rs11587213 | FCER1G | AG | 3 | Toxicity | aspirin | Asthma | Patients with the AG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. | https://www.pharmgkb.org/clinicalAnnotation/1043858680 |
1043858680 | rs11587213 | rs11587213 | FCER1G | GG | 3 | Toxicity | aspirin | Asthma | Patients with the GG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. | https://www.pharmgkb.org/clinicalAnnotation/1043858680 |
1043858685 | rs1143627 | rs1143627 | IL1B | AA | 3 | Toxicity | aspirin | null | Patients with the AA genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer... | https://www.pharmgkb.org/clinicalAnnotation/1043858685 |
1043858685 | rs1143627 | rs1143627 | IL1B | AG | 3 | Toxicity | aspirin | null | Patients with the AG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer... | https://www.pharmgkb.org/clinicalAnnotation/1043858685 |
1043858685 | rs1143627 | rs1143627 | IL1B | GG | 3 | Toxicity | aspirin | null | Patients with the GG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the AG or AA genotype. The study did not discuss the direction of the association but it might be an increased risk. Other genetic and clinical factors may also influence a patient's risk for peptic u... | https://www.pharmgkb.org/clinicalAnnotation/1043858685 |
1043858698 | rs1131882 | rs1131882 | TBXA2R | AA | 3 | Toxicity | aspirin | Asthma | Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858698 |
1043858698 | rs1131882 | rs1131882 | TBXA2R | AG | 3 | Toxicity | aspirin | Asthma | Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858698 |
1043858698 | rs1131882 | rs1131882 | TBXA2R | GG | 3 | Toxicity | aspirin | Asthma | Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma. | https://www.pharmgkb.org/clinicalAnnotation/1043858698 |
1043858703 | rs1062535 | rs1062535 | ITGA2 | AA | 3 | Efficacy | aspirin | Myocardial Infarction | Patients with the AA genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858703 |
1043858703 | rs1062535 | rs1062535 | ITGA2 | AG | 3 | Efficacy | aspirin | Myocardial Infarction | Patients with the AG genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858703 |
1043858703 | rs1062535 | rs1062535 | ITGA2 | GG | 3 | Efficacy | aspirin | Myocardial Infarction | Patients with the GG genotype and Myocardial Infarction may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin as compared to patients with the AG or AA genotype Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858703 |
1043858722 | rs2768759 | rs2768759 | NTRK1 | AA | 3 | Efficacy | aspirin | null | Patients with the AA genotype may have a decreased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858722 |
1043858722 | rs2768759 | rs2768759 | NTRK1 | AC | 3 | Efficacy | aspirin | null | No information are provided for the AC genotype. But patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858722 |
1043858722 | rs2768759 | rs2768759 | NTRK1 | CC | 3 | Efficacy | aspirin | null | Patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858722 |
1043858733 | rs1050891 | rs1050891 | HNMT | AA | 3 | Toxicity | aspirin | null | Patients with the AA genotype may have an increased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. | https://www.pharmgkb.org/clinicalAnnotation/1043858733 |
1043858733 | rs1050891 | rs1050891 | HNMT | AG | 3 | Toxicity | aspirin | null | Patients with the AG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. | https://www.pharmgkb.org/clinicalAnnotation/1043858733 |
1043858733 | rs1050891 | rs1050891 | HNMT | GG | 3 | Toxicity | aspirin | null | Patients with the GG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. | https://www.pharmgkb.org/clinicalAnnotation/1043858733 |
1043858794 | CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*10, CYP2C19*17, CYP2C19*19, CYP2C19*25, CYP2C19*26 | null | CYP2C19 | *1 | 1A | Metabolism/PK | clopidogrel | null | The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele may have increased metabolism of clopidogrel as compared to patients with no or decreased function allele in combination with a normal or increased function allele or... | https://www.pharmgkb.org/clinicalAnnotation/1043858794 |
1043858794 | CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*10, CYP2C19*17, CYP2C19*19, CYP2C19*25, CYP2C19*26 | null | CYP2C19 | *10 | 1A | Metabolism/PK | clopidogrel | null | The CYP2C19*10 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*10 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers t... | https://www.pharmgkb.org/clinicalAnnotation/1043858794 |
1043858794 | CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*10, CYP2C19*17, CYP2C19*19, CYP2C19*25, CYP2C19*26 | null | CYP2C19 | *17 | 1A | Metabolism/PK | clopidogrel | null | The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele with another increased function allele may have increased metabolism of clopidogrel compared to two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased fu... | https://www.pharmgkb.org/clinicalAnnotation/1043858794 |
1043858794 | CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*10, CYP2C19*17, CYP2C19*19, CYP2C19*25, CYP2C19*26 | null | CYP2C19 | *19 | 1A | Metabolism/PK | clopidogrel | null | The CYP2C19*19 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*19 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers t... | https://www.pharmgkb.org/clinicalAnnotation/1043858794 |
1043858794 | CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*10, CYP2C19*17, CYP2C19*19, CYP2C19*25, CYP2C19*26 | null | CYP2C19 | *2 | 1A | Metabolism/PK | clopidogrel | null | The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharma... | https://www.pharmgkb.org/clinicalAnnotation/1043858794 |
1043858794 | CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*10, CYP2C19*17, CYP2C19*19, CYP2C19*25, CYP2C19*26 | null | CYP2C19 | *25 | 1A | Metabolism/PK | clopidogrel | null | The CYP2C19*25 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*25 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers t... | https://www.pharmgkb.org/clinicalAnnotation/1043858794 |
1043858794 | CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*10, CYP2C19*17, CYP2C19*19, CYP2C19*25, CYP2C19*26 | null | CYP2C19 | *26 | 1A | Metabolism/PK | clopidogrel | null | The CYP2C19*26 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*26 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers t... | https://www.pharmgkb.org/clinicalAnnotation/1043858794 |
1043858794 | CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*10, CYP2C19*17, CYP2C19*19, CYP2C19*25, CYP2C19*26 | null | CYP2C19 | *3 | 1A | Metabolism/PK | clopidogrel | null | The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharma... | https://www.pharmgkb.org/clinicalAnnotation/1043858794 |
1043858794 | CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*10, CYP2C19*17, CYP2C19*19, CYP2C19*25, CYP2C19*26 | null | CYP2C19 | *8 | 1A | Metabolism/PK | clopidogrel | null | The CYP2C19*8 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*8 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharma... | https://www.pharmgkb.org/clinicalAnnotation/1043858794 |
1043858840 | rs9332096 | rs9332096 | CYP2C9 | CC | 3 | Dosage | warfarin | null | Patients with the CC genotype may require increased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin. | https://www.pharmgkb.org/clinicalAnnotation/1043858840 |
1043858840 | rs9332096 | rs9332096 | CYP2C9 | CT | 3 | Dosage | warfarin | null | Patients with the CT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin. | https://www.pharmgkb.org/clinicalAnnotation/1043858840 |
1043858840 | rs9332096 | rs9332096 | CYP2C9 | TT | 3 | Dosage | warfarin | null | Patients with the TT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin. | https://www.pharmgkb.org/clinicalAnnotation/1043858840 |
1043858845 | rs833061 | rs833061 | VEGFA | CC | 3 | Toxicity | sunitinib | null | Patients with the CC genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib. | https://www.pharmgkb.org/clinicalAnnotation/1043858845 |
1043858845 | rs833061 | rs833061 | VEGFA | CT | 3 | Toxicity | sunitinib | null | Patients with the CT genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib. | https://www.pharmgkb.org/clinicalAnnotation/1043858845 |
1043858845 | rs833061 | rs833061 | VEGFA | TT | 3 | Toxicity | sunitinib | null | Patients with the TT genotype may be associated with a decreased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib. | https://www.pharmgkb.org/clinicalAnnotation/1043858845 |
1043858872 | rs8060157 | rs8060157 | ZNF423 | AA | 3 | Efficacy | raloxifene;tamoxifen | Breast Neoplasms | Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence ... | https://www.pharmgkb.org/clinicalAnnotation/1043858872 |
1043858872 | rs8060157 | rs8060157 | ZNF423 | AG | 3 | Efficacy | raloxifene;tamoxifen | Breast Neoplasms | Patients with the AG genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence ... | https://www.pharmgkb.org/clinicalAnnotation/1043858872 |
1043858872 | rs8060157 | rs8060157 | ZNF423 | GG | 3 | Efficacy | raloxifene;tamoxifen | Breast Neoplasms | Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also infl... | https://www.pharmgkb.org/clinicalAnnotation/1043858872 |
1043858877 | rs10030044 | rs10030044 | null | GG | 3 | Efficacy | raloxifene;tamoxifen | Breast Neoplasms | Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence ... | https://www.pharmgkb.org/clinicalAnnotation/1043858877 |
1043858877 | rs10030044 | rs10030044 | null | GT | 3 | Efficacy | raloxifene;tamoxifen | Breast Neoplasms | Patients with the GT genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence ... | https://www.pharmgkb.org/clinicalAnnotation/1043858877 |
1043858877 | rs10030044 | rs10030044 | null | TT | 3 | Efficacy | raloxifene;tamoxifen | Breast Neoplasms | Patients with the TT genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence ... | https://www.pharmgkb.org/clinicalAnnotation/1043858877 |
1043858882 | rs731236 | rs731236 | VDR | AA | 3 | Efficacy | calcium | null | Patients with the AA genotype may have decreased risk of bone fractures when treated with Calcium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to calcium. | https://www.pharmgkb.org/clinicalAnnotation/1043858882 |
1043858882 | rs731236 | rs731236 | VDR | AG | 3 | Efficacy | calcium | null | Patients with the AG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium. | https://www.pharmgkb.org/clinicalAnnotation/1043858882 |
1043858882 | rs731236 | rs731236 | VDR | GG | 3 | Efficacy | calcium | null | Patients with the GG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium. | https://www.pharmgkb.org/clinicalAnnotation/1043858882 |
1043858887 | rs717620 | rs717620 | ABCC2 | CC | 3 | Other | erythromycin | null | Patients with the CC genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin. | https://www.pharmgkb.org/clinicalAnnotation/1043858887 |
1043858887 | rs717620 | rs717620 | ABCC2 | CT | 3 | Other | erythromycin | null | Patients with the CT genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin. | https://www.pharmgkb.org/clinicalAnnotation/1043858887 |
1043858887 | rs717620 | rs717620 | ABCC2 | TT | 3 | Other | erythromycin | null | Patients with the TT genotype may have increased metabolism of erythromycin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin. | https://www.pharmgkb.org/clinicalAnnotation/1043858887 |
1043858892 | rs7089580 | rs7089580 | CYP2C9 | AA | 3 | Dosage | warfarin | null | Patients with the AA genotype may require lower dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose. | https://www.pharmgkb.org/clinicalAnnotation/1043858892 |
1043858892 | rs7089580 | rs7089580 | CYP2C9 | TA | 3 | Dosage | warfarin | null | Patients with the TA genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose. | https://www.pharmgkb.org/clinicalAnnotation/1043858892 |
1043858892 | rs7089580 | rs7089580 | CYP2C9 | TT | 3 | Dosage | warfarin | null | Patients with the TT genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose. | https://www.pharmgkb.org/clinicalAnnotation/1043858892 |
1043858905 | rs7903146 | rs7903146 | TCF7L2 | CC | 3 | Efficacy | sulfonamides, urea derivatives | null | Patients with the CC genotype may have increased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CT or TT genotype. Other clinical and genetic factors may also ... | https://www.pharmgkb.org/clinicalAnnotation/1043858905 |
1043858905 | rs7903146 | rs7903146 | TCF7L2 | CT | 3 | Efficacy | sulfonamides, urea derivatives | null | Patients with the CT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influe... | https://www.pharmgkb.org/clinicalAnnotation/1043858905 |
1043858905 | rs7903146 | rs7903146 | TCF7L2 | TT | 3 | Efficacy | sulfonamides, urea derivatives | null | Patients with the TT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influe... | https://www.pharmgkb.org/clinicalAnnotation/1043858905 |
1043858965 | rs5186 | rs5186 | AGTR1 | AA | 3 | Efficacy | captopril | Diabetes Mellitus, Type 2 | Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with captopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to captopril. | https://www.pharmgkb.org/clinicalAnnotation/1043858965 |
1043858965 | rs5186 | rs5186 | AGTR1 | AC | 3 | Efficacy | captopril | Diabetes Mellitus, Type 2 | Patients with the AC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril. | https://www.pharmgkb.org/clinicalAnnotation/1043858965 |
1043858965 | rs5186 | rs5186 | AGTR1 | CC | 3 | Efficacy | captopril | Diabetes Mellitus, Type 2 | Patients with the CC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril. | https://www.pharmgkb.org/clinicalAnnotation/1043858965 |
1043858970 | rs5985 | rs5985 | F13A1 | AA | 3 | Efficacy | aspirin | null | Male patients with the AA genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858970 |
1043858970 | rs5985 | rs5985 | F13A1 | AC | 3 | Efficacy | aspirin | null | Male patients with the AC genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858970 |
1043858970 | rs5985 | rs5985 | F13A1 | CC | 3 | Efficacy | aspirin | null | Male patients with the CC genotype may have a decreased inhibition of FXIII activation by aspirin as compared to the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858970 |
1043858975 | rs4523 | rs4523 | TBXA2R | AA | 3 | Efficacy | aspirin | null | Patients with the AA genotype may have an increased risk for aspirin resistance as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance. | https://www.pharmgkb.org/clinicalAnnotation/1043858975 |
1043858975 | rs4523 | rs4523 | TBXA2R | AG | 3 | Efficacy | aspirin | null | Patients with the AG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance. | https://www.pharmgkb.org/clinicalAnnotation/1043858975 |
1043858975 | rs4523 | rs4523 | TBXA2R | GG | 3 | Efficacy | aspirin | null | Patients with the GG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance. | https://www.pharmgkb.org/clinicalAnnotation/1043858975 |
1043858980 | rs6065 | rs6065 | GP1BA | CC | 3 | Efficacy | aspirin | null | Patients with the rs6065 CC genotype may have a decreased response and an increased risk for aspirin resistance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858980 |
1043858980 | rs6065 | rs6065 | GP1BA | CT | 3 | Efficacy | aspirin | null | Patients with the rs6065 CT genotype may have an increased response and a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858980 |
1043858980 | rs6065 | rs6065 | GP1BA | TT | 3 | Efficacy | aspirin | null | Patients with the rs6065 TT genotype may have an increased response and a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858980 |
1043858990 | rs10306114 | rs10306114 | PTGS1 | AA | 3 | Efficacy | aspirin | Coronary Artery Disease;Myocardial Infarction | Patients with the rs10306114 AA genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858990 |
1043858990 | rs10306114 | rs10306114 | PTGS1 | AG | 3 | Efficacy | aspirin | Coronary Artery Disease;Myocardial Infarction | Patients with the rs10306114 AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858990 |
1043858990 | rs10306114 | rs10306114 | PTGS1 | GG | 3 | Efficacy | aspirin | Coronary Artery Disease;Myocardial Infarction | Patients with the rs10306114 GG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to aspirin. | https://www.pharmgkb.org/clinicalAnnotation/1043858990 |
1043859020 | rs5051 | rs5051 | AGT | CC | 3 | Efficacy | atenolol | Hypertension | Patients with the CC genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol as compared to patients with the CT or TT genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change ... | https://www.pharmgkb.org/clinicalAnnotation/1043859020 |
1043859020 | rs5051 | rs5051 | AGT | CT | 3 | Efficacy | atenolol | Hypertension | Patients with the CT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in sys... | https://www.pharmgkb.org/clinicalAnnotation/1043859020 |
1043859020 | rs5051 | rs5051 | AGT | TT | 3 | Efficacy | atenolol | Hypertension | Patients with the TT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in sys... | https://www.pharmgkb.org/clinicalAnnotation/1043859020 |
1043859029 | rs430397 | rs430397 | HSPA5 | CC | 3 | Efficacy | Platinum compounds | Non-Small Cell Lung Carcinoma | Patients with the CC genotype and non-small cell lung cancer may have an increased response to platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum compounds. | https://www.pharmgkb.org/clinicalAnnotation/1043859029 |
End of preview. Expand in Data Studio
No dataset card yet
- Downloads last month
- 10